Pre-clinical Vaccine Development for Emerging and Re-emerging Infectious Diseases

病毒学核心与其他NIAID内部实验室合作开发了中东呼吸综合征冠状病毒刺突蛋白亚单位疫苗。佐剂中东呼吸综合征冠状病毒刺突蛋白亚单位疫苗可完全保护羊驼免受中东呼吸综合征冠状病毒疾病，并导致单峰骆驼上呼吸道病毒脱落减少和延迟。数据表明，通过接种普通动物疫苗诱导强大的中和性体液免疫反应可以减少脱落，从而可能降低人畜共患病传播的风险。

The Virology Core has collaborated with other intramural NIAID labs to develop a MERS-CoV Spike protein subunit vaccine. A vaccine of adjuvanted MERS-CoV Spike protein subunit vaccine confers complete protection from MERS-CoV disease in alpaca and results in reduced and delayed viral shedding in the upper airways of dromedary camels. The data indicate that induction of robust neutralizing humoral immune responses by vaccination of nave animals reduces shedding that potentially could diminish the risk of zoonotic transmission. During the past year, we focused on isolation of monoclonal antibodies from SARS-CoV, MERS-CoV, and HKU-1 infected patients and vaccinated non-human primates. The monoclonal antibodies were analyzed for their binding and neutralization ability against different coronaviruses. This study successfully assessed some anti-coronavirus monoclonal antibodies with high potency and breath. Those monoclonal antibodies may have potential therapeutic application in fighting infection.